Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, ...

Eli Lilly on Thursday reported promising results for a daily pill that could serve as an alternative to injectable ...

In an hour-long meeting at Eli Lilly and Company’s headquarters in Indianapolis on April 15, the pharmaceutical company’s top ...

Shares of Eli Lilly jumped 12% in premarket trading Thursday after the pharmaceutical company released Phase 3 trial results ...

If approved, the pill is expected to be far easier to administer than current injectables — and far easier to manufacture.

Lilly shares are up 14.2% in response to the news, while shares of its rivals in the GLP-1 weight loss market, Novo Nordisk ( ...

The mid-stage trial results announced by the pharmaceutical giant showed that patients taking orforglipron lost an average of 16 pounds.

Eli Lilly's oral GLP-1 drug orforglipron met key Phase 3 goals in type 2 diabetes, lowering A1C and weight with a favorable ...

Shares in pharmaceuticals firm Eli Lilly (LLY) ballooned higher today after revealing its new needle-free weight loss drug had performed ...

What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 15.3% in the morning session after results ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

GE Aerospace is an American aircraft company, which engages in the provision of jet and turboprop engines, as well as integrated systems for commercial, military, business, and general aviation ...